Top of page
Lawyers

Serdar Inci

Lawyers

Associate in our Corporate practice, based in London.

Serdar advises corporate clients and investment banks on U.S. and international equity and debt capital market transactions (both SEC-registered and unregistered), including IPOs, SPACs, private placements, investment-grade, high-yield and regulatory capital debt offerings, as well as liability management transactions.

In addition, Serdar advises U.S. domestic clients and foreign private issuers on ongoing reporting and disclosure obligations, including compliance with the U.S. Securities Act, the U.S. Exchange Act, the Sarbanes-Oxley Act, NASDAQ rules and corporate governance rules and regulations.

Serdar is bilingual in German and English.

Capabilities
Languages
German
Languages
German

Experience highlights

Serdar has advised clients on a broad range of capital markets transactions, including:

Debt

Issuers

  • A leading U.K. medical technology company on its SEC-registered $1.0 billion notes offering
  • Ferguson on its $600 million Rule 144A and Reg. S notes offering
  • A leading German automobile manufacturer on various Rule 144A and Reg. S notes offerings, totaling U.S. $9 billion
  • The investment banking arm of a Scottish bank on the establishment of its $5 billion U.S. commercial paper program
  • A Swiss multinational healthcare company on the update of its $7.5 billion U.S. commercial paper program

Underwriters/Initial Purchasers

  • Aker BP’s $1.5 billion Rule 144A and Reg. S notes offering
  • Various Anglo American Rule 144A and Reg. S notes offerings, totaling $3.15 billion
  • Several National Grid Rule 144A and Reg. S notes offerings, totaling $1.7 billion
  • AngloGold Ashanti’s SEC registered $750 million notes offering
  • Fresenius Medical Care’s $1.0 billion Rule 144A and Reg. S notes offering
  • Multiple SEC-registered notes offerings of Deutsche Bank, totaling $3.25 billion
  • British American Tobacco’s SEC-registered $2.4 billion notes offering
  • Various SEC-registered notes offerings of Oesterreichische Kontrollbank, totaling $2.5 billion
IPOs and other Equity Offerings

Issuers

  • IONOS Group on its €447 million initial public offering
  • Forbion European Acquisition Corp. on its $110 million initial public offering
  • Target Global Acquisition I Corp. on its $200 million initial public offering
  • Mountain & Co. I Acquisition Corp. on its $230 million initial public offering
  • Oncopeptides on its SEK 1.1 billion (approx. $130 million) private placement of new shares
  • Centogene on its $49 million follow-on offering
  • Xspray Pharma on its SEK 265 million private placement of new shares
  • SEAS-NVE on its DKK 5.4 billion (approx. $800 million) secondary block sale of shares in Ørsted
  • Centogene on its $56 million initial public offering on Nasdaq

Underwriters

  • Investcorp India Acquisition Corp’s $258.5 million initial public offering
  • Levere Holdings Corp.’s $250 million initial public offering
Liability Management Transactions
  • The dealer managers on Aker BP’s $1.1 billion cash tender offer
  • The dealer managers on AngloGold Ashanti’s $750 million cash tender offer
  • NatWest Group plc’s $1.9 billion cash tender offer
View more experience
Education
LL.M., Columbia Law School
  • Dr. Theo Waigel Scholarship
  • Dr. Walter Oppenhoff Scholarship
  • ERP Scholarship
  • Senior Editor, Columbia Journal of European Law
Ph.D., University of Cologne
  • summa cum laude
  • Studienstiftung Scholarship
  • Editor-In-Chief, Cologne Business Law Review
J.D., University of Cologne
  • third in class
  • Dean's Award for Academic Excellence
Professional history
  • Davis Polk since 2018
Qualifications and admissions
  • State of New York
Back to top